ENDRA Life Sciences

NDRA

Market cap $6.95M

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%. These threshold.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease (“MASLD”) and metabolic dysfunction-associated steatohepatitis (“MASH”), today announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key bi.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today provided a business update and reported financial results for the three and nine months ended September 30, 2025. Business Update Completed private placement of up to $14.4 million. On.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced a significant step in its digital asset strategy with the commencement of staking its holdings of HYPE, the native token of the Hyperliquid ecosystem. This strategic move, guided by AR.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), has successfully closed its previously announced private investment in public equity ("PIPE") financing led by institutional and cryptocurrency investors. The PIPE resulted in gross proceeds of approx.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced an aggregate of $4.9 million in commitments for a private placement (the “Offering”) led by leading institutional and cryptocurrency investors. The proceeds will be used to launch a di.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three and six months ended June 30, 2025. Business Update Advanced development of TAEUS Liver. ENDRA advanced its product development work with enhancements to the TAEUS Liver system's probe design and proprietary algorithms, which are expected to deliver significantly improved accuracy and.

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS® Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device's probe design and proprietary algorithms, me.

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease. With a sharpened mission to transform.

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies. ENDRA's management has thoroughly evaluated the Comp.